Truist Securities Maintains Buy on Praxis Precision Medicine, Lowers Price Target to $616

Benzinga Newsdesk www.benzinga.com Negative 81.7%

Neg 81.7% Neu 0% Pos 0%

Truist Securities analyst Danielle Brill maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Buy and lowers the price target from $715 to $616.